Acquiring Company
Day One Biopharmaceuticals
Acquired Company
Mersana Therapeutics
BrisbaneCambridgeBiotechnologyHealth CareTherapeuticsPharmaceuticalBiopharmaBiotechnologyHealth CareTherapeuticsDescription
Day One Biopharmaceuticals has completed the acquisition of Mersana Therapeutics for USD 173.0 million. Shareholders of Mersana received USD 25.00 per share plus a contingent value right that could reach an additional USD 30.25. This acquisition allows Day One to enhance its pipeline with Mersana's clinical-stage assets.
Fundz sees it the moment Day One Biopharmaceuticals makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired Mersana Therapeutics?
Mersana Therapeutics was acquired by Day One Biopharmaceuticals, based in Brisbane. The deal was reported on October 4, 2026. Day One Biopharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases. Day One Biopharmaceuticals is privately held and operates in Biotechnology.
When did Day One Biopharmaceuticals acquire Mersana Therapeutics?
Day One Biopharmaceuticals's acquisition of Mersana Therapeutics was reported on October 4, 2026. Day One Biopharmaceuticals has completed the acquisition of Mersana Therapeutics for USD 173.0 million. Shareholders of Mersana received USD 25.00 per share plus a contingent value right that could reach an additional USD 30.25. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Mersana Therapeutics do?
Mersana Therapeutics, Inc. is a biotechnology company focused on developing next-generation antibody-drug conjugates (ADCs) for cancer treatment. Their innovative ADC platform enables the design of more effective cancer therapies. It is privately held, operating in Biotechnology, and is based in Cambridge.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.